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Abstract
 
Myeloid differentiation factor 88 (MyD88) plays essential roles in the signaling of the Toll/
interleukin (IL)-1 receptor family. Toll–IL-1 receptor domain-containing adaptor induc-
ing  interferon-
 
 
 
 (TRIF)-mediated signals are involved in lipopolysaccharide (LPS)-induced
MyD88-independent pathways. Using MyD88-deficient (MyD88
 
   
 
) mice and TRIF-deficient
(TRIF
 
   
 
) mice, we examined roles of MyD88 and TRIF in osteoclast differentiation and func-
tion. LPS, diacyl lipopeptide, and IL-1
 
 
 
 stimulated osteoclastogenesis in cocultures of osteoblasts
and hemopoietic cells obtained from TRIF
 
   
 
 mice, but not MyD88
 
   
 
 mice. These factors
stimulated receptor activator of nuclear factor-
 
 
 
B ligand mRNA expression in TRIF
 
   
 
 osteo-
blasts, but not MyD88
 
   
 
 osteoblasts. LPS stimulated IL-6 production in TRIF
 
   
 
 osteoblasts,
but not TRIF
 
   
 
 macrophages. LPS and IL-1
 
 
 
 enhanced the survival of TRIF
 
   
 
 osteoclasts, but
not MyD88
 
   
 
 osteoclasts. Diacyl lipopeptide did not support the survival of osteoclasts because
of the lack of Toll-like receptor (TLR)6 in osteoclasts. Macrophages expressed both TRIF and
TRIF-related adaptor molecule (TRAM) mRNA, whereas osteoblasts and osteoclasts expressed
only TRIF mRNA. Bone histomorphometry showed that MyD88
 
   
 
 mice exhibited osteopenia
with reduced bone resorption and formation. These results suggest that the MyD88-mediated
signal is essential for the osteoclastogenesis and function induced by IL-1 and TLR ligands, and
that MyD88 is physiologically involved in bone turnover.
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Introduction
 
Osteoclasts, the multinucleated cells that resorb bone, orig-
inate from monocyte-macrophage lineage cells. Osteoblasts
(or bone marrow stromal cells) are involved in osteoclasto-
genesis (1, 2). Macrophage CSF (M-CSF) produced by osteo-
blasts is an essential factor for osteoclast formation. Receptor
activator of NF-
 
 
 
B ligand (RANKL) is another cytokine
essential for osteoclastogenesis expressed by osteoblasts as a
membrane-associated cytokine (1–5). Osteoclast precursors
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Abbreviations used in this paper:
 
 ERK, extracellular signal-regulated kinase;
MAPK, mitogen-activated protein kinase; M-CSF, macrophage CSF;
MEK, MAPK/ERK kinase; MyD88, myeloid differentiation factor 88;
MyD88
 
   
 
, MyD88-deficient; OPG, osteoprotegerin; PKC, protein kinase
C; RANK, receptor activator of NF-
 
 
 
B; RANKL, RANK ligand; TIR,
Toll/IL-1 receptor; TLR, Toll-like receptor; TRAM, TRIF-related
adaptor molecule; TRAM
 
   
 
, TRAM-deficient; TRAP, tartrate-resistant
acid phosphatase; TRIF, TIR domain-containing adaptor-inducing IFN-
 
 
 
;
TRIF
 
   
 
, TRIF-deficient. 
Role of MyD88 and TRIF in LPS-induced Bone Resorption
 
602
express RANK (a receptor of RANKL), recognize
RANKL expressed by osteoblasts through cell–cell interac-
tion, and differentiate into osteoclasts in the presence of
M-CSF. Osteoprotegerin (OPG) produced mainly by os-
teoblasts is a soluble decoy receptor for RANKL (6). OPG
blocks osteoclastogenesis by inhibiting the RANKL–RANK
interaction. Bone resorption-stimulating hormones and cy-
tokines enhance the expression of RANKL in osteoblasts.
Mature osteoclasts also express RANK, and RANKL sup-
ports the survival and stimulates the bone-resorbing activity
of osteoclasts (1–5).
LPS, a major constituent of gram-negative bacteria, is
proposed to be a potent stimulator of bone resorption in
inflammatory diseases (7). CD14 is a membrane-anchored
glycoprotein that functions as a member of the LPS recep-
tor system. Toll-like receptor (TLR)4 is a critical receptor
and signal transducer for LPS (8, 9). Bacterial lipoprotein/
lipopeptides have pathogen-specific molecular patterns.
The complex of TLR6 and TLR2 recognizes diacyl li-
popeptide (9, 10). We found that lipoproteins derived from
 
Mycoplasma salivarium
 
, a member of the human oral micro-
bial flora, and a synthetic diacyl lipopeptide (FSL-1) acti-
vate human gingival fibroblasts to induce inflammatory cy-
tokine production via p38 mitogen-activated protein kinase
(MAPK)-mediated signals (11).
TLR family members have an intracytoplasmic region,
called the Toll/IL-1 receptor (TIR) homology domain.
Through the homophilic interaction of TIR domains, my-
eloid differentiation factor 88 (MyD88) is associated not
only with cytokine receptors for IL-1 and IL-18 but also
with various TLRs (9, 12). MyD88-deficient (MyD88
 
   
 
)
mice showed resistance to LPS-induced responses includ-
ing cytokine production by macrophages, B cell prolifera-
tion, and endotoxin shock (12, 13). MyD88
 
   
 
 mice did
not respond to IL-1, IL-18, or other microbial cell wall
components such as peptidoglycan and lipopeptides (14).
However, MyD88
 
   
 
 macrophages showed a delayed acti-
vation of NF-
 
 
 
B and MAPK cascades in response to LPS
(13). In addition, LPS induced the functional maturation of
MyD88
 
   
 
 dendritic cells, including the up-regulation of
costimulatory molecules (15). These results indicate the ex-
istence of a MyD88-independent pathway through TLR4.
Recently, TIR domain-containing adaptor-inducing IFN-
 
 
 
(TRIF) was identified as an adopter involved in MyD88-
independent signaling pathways (16). TRIF plays essential
roles in TLR4- and TLR3-mediated pathways (17, 18).
TRIF-related adaptor molecule (TRAM) was identified
as an adopter specifically involved in the TLR4-mediated
MyD88-independent signaling pathway (19, 20). Using
TRIF-deficient (TRIF
 
   
 
) mice and TRAM-deficient
(TRAM
 
   
 
) mice, it was shown that both MyD88-depen-
dent and TRAM–TRIF-dependent pathways were re-
quired for LPS-induced proinflammatory cytokine pro-
duction in macrophages and for LPS-induced activation of
B cells (19). In addition, p38 MAPK- and MAPK/extracel-
lular signal-regulated kinase (ERK) kinase (MEK)/ERK-
mediated signals are shown to be involved in LPS-induced
proinflammatory cytokine production in human osteoblas-
tic cells (21).
Using MyD88
 
   
 
 mice and TRIF
 
   
 
 mice, we explored
the roles of MyD88 and TRIF in osteoclast differentiation
and function induced by LPS, IL-1
 
 
 
, and diacyl lipopeptide.
We also examined whether both MyD88 and TRIF signals
are involved in cytokine production in osteoblasts as well as
bone marrow macrophages. We have shown that MyD88-
mediated signals, but not TRIF-mediated signals, induced
RANKL expression in osteoblasts. LPS stimulated IL-6 pro-
duction in TRIF
 
   
 
 osteoblasts, but not TRIF
 
   
 
 macro-
phages. MyD88- but not TRIF-mediated signals supported
the survival of osteoclasts induced by LPS. Bone histomor-
phometry revealed that MyD88
 
   
 
 mice exhibited typical
osteopenia with reduced bone resorption and formation.
 
Materials and Methods
 
Animals and Drugs.
 
MyD88
 
   
 
, TLR4-deficient (TLR4
 
   
 
),
and TRIF
 
   
 
 mice with the genetic background of C57BL/6J
were generated and maintained as described previously (12, 17,
22). After heterozygous (
 
   
 
) mating, heterozygous (
 
   
 
), ho-
mozygous (
 
   
 
), and WT (
 
   
 
) mice were identified by PCR
analysis of DNA obtained from the tail of each mouse. WT
(C57BL/6J) mice were obtained from Japan Clea Co. All proce-
dures for animal care were approved by the Animal Management
Committee of Matsumoto Dental University. LPS (
 
Escherichia coli
 
O55:B5) and H-89 were purchased from Sigma-Aldrich. A syn-
thetic diacyl lipopeptide (FSL-1) was prepared as described previ-
ously (23). PD98059, BAPTA-AM, Ro-32-0432, A23187, and
phorbol-12-myristate-13-acetate (PMA) were obtained from Cal-
biochem Co. Recombinant human soluble RANKL and human
OPG were purchased from PeproTech. Recombinant mouse IL-
1
 
 
 
 was obtained from Genzyme. Recombinant human M-CSF
(Leukoprol) was obtained from Kyowa Hakko Kogyo Co. 1
 
 
 
,25-
dihydroxyvitamin D
 
3
 
 [1,25(OH)
 
2
 
D
 
3
 
] and prostaglandin E
 
2
 
 (PGE
 
2
 
)
were purchased from Wako Pure Chemical Industries Ltd. Rabbit
anti–mouse phospho-ERK1/2 (Thr202/Tyr204) antibody and
rabbit anti–mouse ERK1/2 antibody were purchased from Cell
Signaling Technology Inc. An ELISA kit for mouse IL-6 was ob-
tained from R&D Systems. Specific PCR primers for mouse
TLR2, TLR4, TLR6, IL-1R, CD14, RANKL, TRIF, and
TRAM and GAPDH were synthesized by Invitrogen. Other
chemicals and reagents were of analytical grade.
 
Osteoclast Differentiation Assay.
 
To isolate primary osteoblasts
from either MyD88
 
   
 
, TLR4
 
   
 
, TRIF
 
   
 
, or WT mice, cal-
varia from 2-d-old mice (male and female) were cut into small
pieces and cultured for 5 d in type I collagen gel (cell matrix
type-IA; Nitta Gelatin, Inc.) prepared in an 
 
 
 
-MEM (Sigma-
Aldrich) containing 10% FBS (JRH Biosciences; reference 6). Os-
teoblasts grown from the calvarium were collected by treating the
collagen gel cultures with collagenase and stored at 
 
 
 
80
 
 
 
C before
use. Bone marrow cells obtained from tibiae of 5–8-wk-old male
mice were suspended in an 
 
 
 
-MEM supplemented with 10%
FBS in 60-mm-diameter dishes for 16 h in the presence of 50 ng/
ml M-CSF. Next, nonadherent cells were harvested as hemopoi-
etic cells. The hemopoietic cells (1.5 
 
 
 
 10
 
5
 
 cells/well) were co-
cultured with osteoblasts (1.5 
 
 
 
 10
 
4
 
 cells/well) prepared from
each mouse for 7 d in a 48-well plate with 0.3 ml of 
 
 
 
-MEM
containing 10% FBS in the presence of test chemicals. In some
experiments, the hemopoietic cells prepared from male MyD88
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and WT mice were cultured in the presence of 100 ng/ml
RANKL and 50 ng/ml M-CSF for 5 d. All cultures were incu-
bated in quadruplicate, and cells were replenished on day 3 with
fresh medium. Adherent cells were fixed with 10% formaldehyde
in PBS, treated with ethanol-acetone (50:50), and stained for tar-
trate-resistant acid phosphatase (TRAP, a marker enzyme of os-
teoclasts) as described previously (24). TRAP positive multinu-
cleated cells containing more than three nuclei were counted as
osteoclasts. The results obtained from one experiment typical of
at least three independent experiments were expressed as the
mean 
 
 
 
 SEM of three cultures. The significance of the differ-
ences was determined using Student’s 
 
t
 
 test.
 
Survival Assay of Mature Osteoclasts.
 
Osteoblasts and freshly
prepared bone marrow cells were cocultured in 
 
 
 
-MEM con-
taining 10% FBS and 10
 
 
 
8
 
 M 1,25(OH)
 
2
 
D
 
3
 
 and 10
 
 
 
6
 
 M PGE
 
2
 
 in
100-mm-diameter dishes precoated with type I collagen gel as
described previously (24). Osteoclasts were formed within 6 d in
the cocultures. All the cells in the cocultures were recovered
from the dishes by treatment with 
 
 
 
-MEM containing 0.3% col-
lagenase (Wako Pure Chemical Industries Ltd.). The cocultures
at day 6 contained 
 
 
 
5% osteoclasts. To purify osteoclasts, the
crude osteoclast preparation was plated in 48-well culture dishes.
After cells were incubated for 6 h, osteoblasts were removed by
treatment with trypsin (0.05%) and EDTA (0.53 mM; Invitro-
gen) for 5 min on the dishes. Some cultures were fixed and
stained for TRAP. These cultures contained 
 
 
 
95% osteoclasts.
Purified osteoclasts were further incubated for 24 h in the pres-
ence of test chemicals and stained for TRAP. TRAP positive
multinucleated cells containing more than three nuclei were
counted as osteoclasts. The results were expressed as the mean 
 
 
 
SEM of three cultures.
 
Preparation of Bone Marrow Macrophages.
 
Bone marrow mac-
rophages were prepared from MyD88
 
   
 
, TRIF
 
   
 
, and WT
mice to examine LPS-induced IL-6 production. Bone marrow
cells obtained from tibiae of MyD88
 
   
 
, TRIF
 
   
 
, and WT mice
(5–8-wk-old adults) were cultured for 16 h in 
 
 
 
-MEM supple-
mented with 10% FBS in the presence of 50 ng/ml M-CSF.
Nonadherent cells were harvested as hemopoietic cells and fur-
ther cultured with 50 ng/ml M-CSF for 2 d. Adherent cells were
used as bone marrow macrophages. Bone marrow macrophages
were incubated for 24 h with 100 ng/ml LPS in the presence of
50 ng/ml M-CSF, and the conditioned medium was collected for
the determination of IL-6.
 
PCR Amplification of Reverse-transcribed mRNA.
 
For semi-
quantitative RT-PCR analysis, osteoblasts prepared from the
MyD88
 
   
 
, TRIF
 
   
 
, or WT mice were cultured in 
 
 
 
-MEM
containing 10% FBS in the presence of test chemicals on 60-mm-
diameter dishes. After cells were cultured, total cellular RNA was
extracted from osteoblasts using TRIzol solution (Life Technolo-
gies). First-strand cDNA was synthesized from total RNA with
random primers and subjected to PCR amplification with EX
 
Taq
 
 polymerase (Takara Biochemicals) using specific PCR prim-
ers: mouse, TLR2, forward, 5
 
 
 
-AAACAACTTACCGAAAC-
CTCAGAC-3
 
 
 
 (nucleotides 273–296) and reverse, 5
 
 
 
-TGTA-
AATTTGTGAGATTGGGAAAA-3
 
 
 
 (nucleotides 748–771);
mouse, TLR4, forward, 5
 
 
 
-AGTGGGTCAAGGAACAGAA-
GCA-3
 
 
 
 (nucleotides 1766–1787) and reverse, 5
 
 
 
-CTTTAC-
CAGCTCATTTCTCACC-3  (nucleotides 2055–2076); mouse
TLR6, forward, 5 -GCCTGACTCTTACAGGTGTGACTA-
3  (nucleotides 1698–1721) and reverse, 5 -TTATGATGGG-
ACAAATAGAGTTCA-3  (nucleotides 2175–2198); mouse
CD14, forward, 5 -ACATCTTGAACCTCCGCAAC-3  (nu-
cleotides 454–473) and reverse, 5 -AGGGTTCCTATCCAGC-
CTGT-3  (nucleotides 934–953); mouse IL-1R, forward, 5 -
TAATGAGTTACCCGAGGTCCA-3  (nucleotides 570–590)
and reverse, 5 -AGGCATCGTATGTCTTTCCA-3  (nucleotides
1257–1276); mouse RANKL, forward, 5 -CGCTCTGTTCCT-
GTACTTTCGAGCG-3  (nucleotides 195–219) and reverse, 5 -
TCGTGCTCCCTCCTTTCATCAGGTT-3  (nucleotides 757–
781); mouse TRIF, forward, 5 -ATGGATAACCCAGGGC-
CTT-3  (nucleotides 187–205) and reverse, 5 -TTCTGGTCA-
CTGCAGGGGAT-3  (nucleotides 696–715); mouse TRAM,
forward, 5 -ATGGCCAGTCCTGGACTTC-3  (nucleotides
126–144) and reverse, 5 -CAAGCAGGCTTCCTCAGAATT-
3  (nucleotides 576–596); and mouse GAPDH, forward, 5 -ACC-
ACAGTCCATGCCATCAC-3  (nucleotides 566–585) and
reverse, 5 -TCCACCACCCTGTTGCTGTA-3  (nucleotides
998–1017). The PCR products were separated by electrophoresis
on 2% agarose gels and visualized by ethidium bromide staining
with UV light illumination. The sizes of the PCR products for
mice TLR2, TLR4, TLR6, CD14, IL-1R, RANKL, TRIF,
TRAM, and GAPDH are 499, 311, 501, 500, 707, 587, 535,
476, and 452 bp, respectively.
Northern Blot Analysis. WT mouse-derived osteoblasts (106
cells) were seeded in cell culture dishes (60 mm in diameter) and
cultured in  -MEM containing 10% FBS for 3 d. After incubation
in  -MEM containing 0.1% FBS for 3 h, cells were treated with
LPS for 3 h. Some cultures were also treated with several kinds of
signal inhibitors for 1 h before the addition of LPS. Total RNA
was isolated from cultures using TRIzol. Northern blot analysis
was performed using denaturing formaldehyde/agarose gels as de-
scribed previously (25). Double stranded complementary DNA
(cDNA) fragments encoding mouse RANKL were provided by
H. Yasuda (Snow Brand Milk Products, Tokyo, Japan). cDNA
probes (RANKL and  -tubulin) labeled with 32P were synthe-
sized using a cDNA labeling kit (Takara). The RANKL and
 -tubulin probes were hybridized with membranes to which total
RNA isolated from osteoblasts had been transferred. The mem-
branes were exposed to Kodak BioMax MS film. Signals for
RANKL and  -tubulin mRNA were quantified using a radioac-
tive image analyzer (BAS2000; Fuji Photo Film Co., Ltd.). Signals
for RANKL were normalized with the respective  -tubulin
mRNA expression levels to calculate the relative intensity.
Western Blot Analysis. Confluent MyD88   - and WT
mouse-derived osteoblasts were further incubated with test
chemicals for 30 min, washed twice with PBS, and lysed in cell
lysate buffer. Whole cell extracts were electrophoresed on a 10%
SDS-polyacrylamide gel and transferred onto nitrocellulose mem-
brane (Millipore). After blocking with 5% skim milk in Tris-buf-
fered saline containing 0.1% Tween 20 (TBS-T), the antiphos-
pho-ERK1/2 antibody or anti-ERK antibody (1:1,000) was added
to TBS-T containing 5% skim milk and the bound antibodies
were visualized using the enhanced chemiluminescence assay
with reagents from Amersham Biosciences followed by exposure
to X-ray film.
Bone Histomorphometry. Seven male MyD88    and WT (14-
wk-old) mice were killed for bone histomorphometric analysis.
For in vivo fluorescent labeling, intraperitoneal injections of tet-
racycline hydrochloride (Sigma-Aldrich) (30 mg/kg of body
weight) and calcein (Sigma-Aldrich) (6 mg/kg of body weight)
were administered at days 0 and 2. Mice were killed on day 4.
Their vertebrae were removed, fixed in 70% ethanol, and em-
bedded in glycol-methacrylate without decalcification. Sections
were prepared and stained with Villanueva Goldner to discrimi-
nate between mineralized and unmineralized bone and to iden-
tify cellular components. Quantitative histomorphometric analy-Role of MyD88 and TRIF in LPS-induced Bone Resorption 604
sis was conducted in a blind fashion. Images were also visualized
by fluorescent microscopy. Nomenclature and units were used
according to the recommendation of the Nomenclature Com-
mittee of the American Society for Bone and Mineral Research
(26). Statistical analysis was done using Student’s t test.
Tissue Preparation for the Histological Analysis of Bone. 12-wk-
old MyD88    and WT mice (two males of each type) were
anesthetized with sodium pentobarbital (Nembutal; Dainippon
Pharmaceutical Co., Ltd.), and perfused for 15 min with 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.3, through
the left ventricle. Tibiae were removed and immersed into the
same fixative for 20 h at 4 C. Specimens were washed with the
phosphate buffer, and decalcified in 10% EDTA, pH 7.3, for 2
wk at 4 C. Decalcified specimens were dehydrated in a graded
series of ethanol solutions, embedded in paraffin, and cut into
4- m-thick sections. TRAP staining was performed on the spec-
imens as described previously (27, 28) and TRAP positive osteo-
clasts were detected under a light microscope.
Results
MyD88 Is an Essential Molecule for Osteoclastogenesis In-
duced by LPS, IL-1 , and Diacyl Lipopeptide First, we ex-
amined the effects of LPS, IL-1 , and a synthetic diacyl li-
popeptide (FSL-1) on osteoclast formation in the murine
coculture system. LPS, IL-1 , and diacyl lipopeptide as
well as 1,25(OH)2D3 plus PGE2 stimulated the formation
of TRAP positive osteoclasts (cells stained red) in cocul-
tures of primary osteoblasts and bone marrow–derived he-
mopoietic cells obtained from WT mice (Fig. 1, A and B).
In contrast, LPS, IL-1 , and diacyl lipopeptide did not in-
Figure 1. MyD88 is essential
for osteoclastogenesis induced by
LPS, IL-1 , and diacyl lipopep-
tide. (A and B) Effects of
1,25(OH)2D3 plus PGE2, LPS,
IL-1 , and diacyl lipopeptide on
osteoclast formation in cocultures
of osteoblasts and hemopoietic
cells prepared from male WT
and MyD88    mice. Calvarial
osteoblasts (1.5   104 cells/well)
and bone marrow–derived he-
mopoietic cells (1.5   105 cells/
well) prepared from WT and
MyD88    mice were cocultured
for 7 d in a 48-well plate in the
presence or absence of 1  g/ml
LPS, 10 ng/ml IL-1 , 10 8 M
diacyl lipopeptide, and 10 8 M
1,25(OH)2D3 plus 10 6 M PGE2.
Cells were fixed and stained
for TRAP. TRAP positive os-
teoclasts appeared dark red (A).
Bar, 100  m (A). TRAP positive
multinucleated cells containing
three or more nuclei were counted
as osteoclasts (B). Values were ex-
pressed as the mean   SD of three cultures. Significant difference between WT and MyD88    cultures (*, P   0.005). (C) Effect of M-CSF plus
RANKL on osteoclast formation in hemopoietic cells prepared from WT and MyD88    mice. Bone marrow–derived hemopoietic cells (1.5   105
cells/well) prepared from WT and MyD88    mice were cultured for 5 d in the presence of 50 ng/ml M-CSF plus 100 ng/ml RANKL. Cells were
fixed and stained for TRAP. TRAP positive multinucleated cells containing three or more nuclei were counted as osteoclasts. Values were expressed as
the mean   SD of three cultures. Experiments were repeated five times with similar results.
Figure 2. MyD88-mediated signals are involved in RANKL expression
in osteoblasts treated with LPS, diacyl lipopeptide, and IL-1 . (A) Expression
of TLR2, TLR4, TLR6, IL-1R, and CD14 in osteoblasts prepared from
WT and MyD88    mice. Osteoblasts prepared from WT and MyD88   
mice were cultured in 60-mm-diameter dishes. Total cellular RNA was ex-
tracted from osteoblasts, reverse transcribed, and amplified by PCR for
mouse TLR2 (32 cycles), TLR4 (32 cycles), TLR6 (32 cycles), IL-1R (32
cycles), CD14 (32 cycles), or GAPDH (20 cycles) using the specific primers
described in Materials and Methods. (B) Effects of LPS, IL-1 ,
1,25(OH)2D3, and diacyl lipopeptide on RANKL mRNA expression in os-
teoblasts prepared from WT and MyD88    mice. WT and MyD88    os-
teoblasts were treated with or without 1  g/ml LPS, 10 ng/ml IL-1 , 10 8 M
1,25(OH)2D3 (1,25D3), and 10 8 M diacyl lipopeptide for the periods in-
dicated. Total cellular RNA was extracted from osteoblasts, reverse tran-
scribed, and amplified by PCR for mouse RANKL (28 cycles) or GAPDH
(20 cycles) using the specific primers described in Materials and Methods.Sato et al. 605
duce osteoclast formation in the coculture of MyD88   -
derived osteoblasts and hemopoietic cells (Fig. 1, A and B).
The number of osteoclasts that formed in response to
1,25(OH)2D3 plus PGE2 in cocultures prepared from
MyD88    mice was always significantly smaller than that
from WT mice (Fig. 1, A and B). In contrast, bone mar-
row–derived hemopoietic cells obtained from MyD88   
mice and those from WT mice similarly differentiated into
osteoclasts in response to RANKL plus M-CSF (Fig. 1 C).
100 ng/ml OPG completely inhibited the osteoclast for-
mation induced by LPS, IL-1 , diacyl lipopeptide, and
1,25(OH)2D3 plus PGE2 in WT cocultures (unpublished
data). These results suggest that MyD88-mediated signals
are important to osteoblasts but not osteoclast precursors in
the osteoclast formation induced by LPS, IL-1 , and diacyl
lipopeptide in the coculture system.
RT-PCR analysis showed that primary osteoblasts ob-
tained from WT and MyD88    mice similarly expressed
TLR2, TLR4, TLR6, IL-1R, and CD14 mRNAs (Fig. 2
A). These results suggest that osteoblasts express LPS re-
ceptors (TLR4 and CD14), diacyl lipopeptide receptors
(TLR2 and TLR6), and IL-1R. Treatment of WT osteo-
blasts with LPS, IL-1 , and diacyl lipopeptide stimulated
the expression of RANKL mRNA within 24 h (Fig. 2 B).
However, these bacterial components and IL-1  failed to
enhance RANKL mRNA expression in MyD88    osteo-
blasts. 1,25(OH)2D3 stimulated the expression of RANKL
mRNA in WT and MyD88    osteoblasts (Fig. 2 B).
These results suggest that the MyD88-mediated pathway is
essentially involved in osteoclast formation induced by LPS,
diacyl lipopeptide, and IL-1  through the expression of
RANKL in osteoblasts.
LPS Stimulates RANKL Expression in Osteoblasts through
MyD88 followed by Protein Kinase C (PKC) and MEK/ERK
Signals. We have shown that LPS stimulates osteoclast for-
mation in the coculture through two parallel events: direct
enhancement of RANKL expression and indirect suppres-
sion of OPG expression, which is mediated by PGE2 pro-
duction (29). Northern blot analysis confirmed that LPS
stimulated the expression of RANKL mRNA in osteoblasts
(Fig. 3 A). Kikuchi et al. (30) reported previously that LPS-
induced RANKL expression was mediated by PKC- and
ERK-mediated signals. We also showed that PMA (a potent
PKC activator), high concentrations of extracellular Ca2 ,
and compounds such as A23187 (an intracellular calcium-
elevating compound) stimulated RANKL expression in os-
teoblasts (25). Next, we examined how MyD88 is involved
in the RANKL expression induced by PKC-, ERK-, and
intracellular calcium-mediated signals in osteoblasts. Pre-
treatment of osteoblasts with BAPTA-AM (an intracellu-
lar calcium chelator), Ro-32-0432 [a PKC inhibitor],
and PD98059 [a MEK/ERK inhibitor] strongly inhibited
RANKL mRNA expression induced by LPS (Fig. 3 A). In
contrast, H-89 (a protein kinase A inhibitor) failed to inhibit
LPS-induced RANKL mRNA expression in osteoblasts
(Fig. 3 A). A23187 and PMA stimulated the expression of
Figure 3. LPS stimulates RANKL ex-
pression in osteoblasts through MyD88 fol-
lowed by PKC and MEK/ERK signals. (A)
Effects of several inhibitors on LPS-induced
RANKL mRNA expression in WT osteo-
blasts. Osteoblasts were pretreated for 1 h
with 10 5 M BAPTA-AM (BAPTA), 10 6
M Ro-32-0432 (Ro), 10 6 M H-89, or
10 5 M PD98059 (PD) and further treated
with 1  g/ml LPS for 3 h. Total RNA was
isolated from osteoblasts, and the expression
of RANKL and  -tubulin mRNAs was an-
alyzed by Northern blotting. Figures below
the signals represent the intensity of
RANKL mRNA expression relative to
 -tubulin mRNA expression. (B) Effects of
PD98059 on RANKL mRNA expression
induced by A23187, PMA, or PGE2 in WT
osteoblasts. Osteoblasts were pretreated for
1 h with 10 5 M PD98059 (PD), and further
treated with or without 10 6 M A23187,
10 6 M PMA, or 10 6 M PGE2 for 3 h.
Total RNA was isolated from osteoblasts,
and the expression of RANKL and  -tubulin
mRNAs was analyzed by Northern blot-
ting. Figures below the signals represent the intensity of RANKL mRNA expression relative to  -tubulin mRNA expression. (C) Effects of
1,25(OH)2D3, LPS, IL-1 , and extracellular Ca2  on phosphorylation of ERK1/2 in osteoblasts prepared from WT and MyD88    mice. WT and
MyD88    osteoblasts were treated with or without 10 8 M 1,25(OH)2D3 (1,25D3), 1  g/ml LPS, 10 ng/ml IL-1 , and 5 mM high calcium medium
(final concentration). After culture for 30 min, cells were washed twice with PBS and lysed in cell lysate buffer. Whole cell extracts were electrophoresed on
a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. After blocking, the antiphospho-ERK1/2 antibody or anti-ERK anti-
body (1:1,000) was added and the bound antibodies were visualized using the enhanced chemiluminescence assay followed by exposure to X-ray film.
(D) Effects of extracellular Ca2  on RANKL mRNA expression in osteoblasts prepared from WT and MyD88    mice. WT and MyD88    osteoblasts
were treated with or without high calcium medium (5 mM, final concentration) for 24 h. Total cellular RNA was extracted from osteoblasts, reverse
transcribed, and amplified by PCR for mouse RANKL (28 cycles) or GAPDH (20 cycles) using specific primers.Role of MyD88 and TRIF in LPS-induced Bone Resorption 606
RANKL mRNA in osteoblasts (Fig. 3 B). Pretreatment of
osteoblasts with PD98059 suppressed RANKL mRNA ex-
pression induced by A23187 and PMA as well as LPS (Fig.
3 B). In contrast, PD98059 showed no inhibitory effect on
the PGE2-induced expression of RANKL mRNA in osteo-
blasts (Fig. 3 B). These results suggested that MEK/ERK is
a down-stream target of PKC-mediated signals in LPS-
induced RANKL expression in osteoblasts.
Next, we examined the effects of 1,25(OH)2D3, LPS, IL-
1 , and high concentrations of extracellular Ca2  on the
phosphorylation of ERK1/2 in osteoblasts prepared from
MyD88    and WT mice. LPS and IL-1  stimulated phos-
phorylation of ERK1/2 within 30 min in WT osteoblasts,
but not in MyD88    osteoblasts (Fig. 3 C). This indicates
that the MyD88 signal is essential for LPS-induced phos-
phorylation of ERK1/2 in osteoblasts. In contrast, high cal-
cium concentrations in the culture medium (5 mM, final
concentration) stimulated the phosphorylation of ERK1/2
and the expression of RANKL mRNA in both MyD88   
and WT osteoblasts (Fig. 3, C and D). This suggests that the
MEK/ERK signals in osteoblasts are active even in the ab-
sence of MyD88. 1,25(OH)2D3 did not induce the phos-
phorylation of ERK1/2 in either type of osteoblast (Fig. 3
C). These results suggest that MyD88 is located upstream of
PKC/ERK signals in the pathway leading to RANKL ex-
pression induced by LPS and IL-1  in osteoblasts.
TRIF Is Not Involved in Osteoclast Formation in the Cocul-
tures. Both MyD88-dependent and TRIF-dependent path-
ways are essential for proinflammatory cytokine production
induced by LPS in peritoneal macrophages (17, 18). Using
TRIF    mice, we examined the importance of TRIF-medi-
ated signals in LPS-induced osteoclast formation. LPS stimu-
lated osteoclast formation in cocultures prepared from TRIF   
mice as well as WT mice (Fig. 4 A). Similarly, IL-1  and
diacyl lipopeptide stimulated osteoclast formation in cocul-
tures prepared from TRIF    mice (Fig. 4 A). Consistent
with these results, treatment of TRIF    osteoblasts with LPS,
IL-1 , diacyl lipopeptide or 1,25(OH)2D3 for 24 h stimulated
the expression of RANKL mRNA (Fig. 4 B). These results
suggest that the TRIF-mediated pathway is not involved in
osteoclast formation induced by IL-1 and TLR ligands.
Next, we examined proinflammatory cytokine produc-
tion in osteoblasts and macrophages prepared from TRIF   
and MyD88    mice. Treatment with LPS for 24 h stim-
ulated IL-6 production in TRIF    and WT osteoblasts,
but not in MyD88    osteoblasts (Fig. 4 C). LPS stimulated
IL-6 production in WT bone marrow macrophages, but
not in TRIF    or MyD88    bone marrow macrophages
(Fig. 4 D). These results suggest that the TRIF-dependent
pathway is involved in LPS-induced IL-6 production in
macrophages but not in osteoblasts.
MyD88 Is Involved in the Survival of Osteoclasts Supported
by LPS and IL-1 . We reported previously that purified
osteoclasts spontaneously died due to apoptosis within 36 h,
and LPS and IL-1  promoted the survival of osteoclasts (31,
32). Next, we examined whether the survival of osteoclasts
supported by LPS, IL-1 , and diacyl lipopeptide is mediated
by MyD88, TRIF, or both. Purified osteoclasts were pre-
Figure 4. TRIF is not involved
in osteoclast differentiation in-
duced by TLR4 ligand. (A) Effects
of 1,25(OH)2D3 plus PGE2, LPS,
IL-1 , and diacyl lipopeptide on
osteoclast formation in cocultures
of osteoblasts and hemopoietic
cells prepared from WT and
TRIF    mice. Calvarial osteo-
blasts (1.5   104 cells/well) and
bone marrow–derived hemopoi-
etic cells (1.5   105 cells/well)
prepared from WT and TRIF   
mice were cocultured for 7 d in a
48-well plate in the presence or
absence of 1  g/ml LPS, 10 ng/
ml IL-1 , 10 8 M diacyl lipopep-
tide,  and 10 8 M 1,25(OH)2D3
plus 10 6 M PGE2. Cells were
fixed and stained for TRAP.
TRAP positive multinucleated
cells containing three or more
nuclei were counted as osteo-
clasts. Values were expressed as
the mean   SD of three cultures. (B) Effects of LPS, IL-1 , 1,25(OH)2D3, and diacyl lipopeptide on RANKL mRNA expression in osteoblasts prepared
from WT and TRIF    mice. WT and TRIF    osteoblasts were treated with or without 1  g/ml LPS, 10 ng/ml IL-1 , 10 8 M 1,25(OH)2D3
(1,25D3), and 10 8 M diacyl lipopeptide for 24 h. Total cellular RNA was extracted from osteoblasts, reverse transcribed, and amplified by PCR for
mouse RANKL (28 cycles) or GAPDH (20 cycles) using specific primers. (C) Effects of LPS on the production of IL-6 in osteoblasts prepared from WT,
TRIF   , and MyD88    mice. Osteoblasts were incubated for 24 h in the presence or absence of 100 ng/ml LPS. The conditioned medium was
collected, and the concentration of IL-6 in the medium was measured using an ELISA kit. Values are expressed as the mean   SD of quadruplicate cul-
tures. (D) Effects of LPS on the production of IL-6 in M-CSF–treated bone marrow macrophages prepared from WT, TRIF   , and MyD88    mice.
Bone marrow–derived macrophages were incubated for 24 h in the presence or absence of 100 ng/ml LPS. The conditioned medium was collected, and
the concentration of IL-6 in the medium was measured using an ELISA kit. Values are expressed as the mean   SD of quadruplicate cultures.Sato et al. 607
pared from cocultures of osteoblasts and bone marrow cells
obtained from WT, MyD88   , TLR4   , and TRIF   
mice. Most of the osteoclasts died spontaneously and disap-
peared within 24 h. RANKL promoted the survival of os-
teoclasts derived from MyD88   , TLR4   , and TRIF   
mice. LPS and IL-1  supported the survival of WT and
TRIF    osteoclasts, but not MyD88    osteoclasts (Fig. 5).
IL-1  and RANKL, but not LPS, promoted the survival of
osteoclasts derived from TLR4    mice. Diacyl lipopeptide
(a ligand for the TLR2 plus TLR6 complex) did not support
the survival of osteoclasts derived from any of the mice.
Takami et al. (33) reported that mature osteoclasts expressed
the mRNA of TLR2 and TLR4, but not TLR6. We have
confirmed that TLR6 mRNA is not expressed in mature os-
teoclasts (unpublished data). These results suggest that diacyl
lipopeptide did not support the survival of osteoclasts because
of the lack of TLR6 in osteoclasts. Thus, MyD88-mediated
signals, but not TRIF-mediated ones, were essential for the
survival of osteoclasts supported by LPS and IL-1 .
TRAM Is Not Expressed in Osteoblasts and Osteoclasts.
TRAM was shown to be involved in the LPS-induced,
TRIF-mediated signaling pathway (19, 20). We examined
the expression of TRIF and TRAM mRNAs in osteo-
blasts, bone marrow macrophages, and osteoclasts prepared
from MyD88   , TRIF   , and WT mice. TRIF mRNA
was expressed in osteoblasts, macrophages, and osteoclasts
derived from WT and MyD88    mice (Fig. 6). Interest-
ingly, TRAM was expressed in macrophages, but not in
osteoblasts or mature osteoclasts (Fig. 6). The fact that
TRIF-mediated signals are not required for LPS-induced
RANKL expression in osteoblasts and osteoclast survival
may be related to the lack of TRAM expression in osteo-
blasts and osteoclasts.
MyD88 /  Mice Exhibited Profound Osteopenia with Re-
duced Bone Resorption and Formation. Histomorphometric
measurements of vertebrae showed that MyD88    mice
exhibited osteopenia with reduced bone resorption and
formation. Bone resorption–related parameters such as os-
teoclast surface/bone surface and osteoclast number/bone
surface were 37.4 and 46.8% lower in MyD88    mice
than WT mice, respectively (Fig. 7 A). Bone formation–
related parameters such as osteoid volume/tissue volume
and osteoblast surface/bone surface were also significantly
reduced in MyD88    mice (Fig. 7 A). Both trabecular
bone volume (bone volume per tissue volume) and tra-
becular number were significantly decreased in 14-wk-old
MyD88    mice in comparison with the WT mice. No
significant differences in body size and shape were observed
between MyD88    and WT mice (unpublished data).
Histological analysis showed that a loss of trabecular bone
in the tibiae was evident in MyD88    mice. The number
of TRAP positive osteoclasts (cells stained red) was reduced
in MyD88    mice compared with WT mice (Fig. 7 B).
These results suggest that MyD88 is involved in the physi-
ological regulation of bone resorption and formation.
Discussion
Using MyD88    and TRIF    mice, we examined the
possible involvement of MyD88 and TRIF in osteoclast dif-
ferentiation and function. LPS, diacyl lipopeptide, and IL-1 
Figure 5. Effects of RANKL, LPS,
IL-1 , and diacyl lipopeptide on the
survival of osteoclasts prepared from
WT, MyD88   , TLR4   , and
TRIF    mice. Purified osteoclasts
were prepared in cocultures of osteo-
blasts and bone marrow cells obtained
from WT, MyD88   , TLR4   , and
TRIF    mice. WT, MyD88   ,
TLR4   , and TRIF    osteoclasts
were treated with or without 100
ng/ml RANKL, 1  g/ml LPS, 10
ng/ml IL-1 , and 10 8 M diacyl li-
popeptide. After culture for 24 h, cells
were fixed and stained for TRAP.
TRAP positive multinucleated cells
containing three or more nuclei were
counted as viable osteoclasts. Values
were expressed as the mean   SD of
three cultures. Experiments were re-
peated five times with similar results.
Figure 6. Expression of TRIF and TRAM in osteoblasts, macrophages
and mature osteoclasts. Expression of TRIF and TRAM in osteoblasts,
macrophages and osteoclasts prepared from WT, TRIF   , and MyD88   
mice. Total cellular RNA was extracted from osteoblasts, M-CSF-induced
bone marrow macrophages, and osteoclasts; reverse transcribed; and ampli-
fied by PCR for mouse TRIF (30 cycles), TRAM (30 cycles), or GAPDH
(18 cycles) using the specific primers described in Materials and Methods.Role of MyD88 and TRIF in LPS-induced Bone Resorption 608
all stimulated osteoclast formation in cocultures of osteoblasts
and hemopoietic cells obtained from WT and TRIF    mice,
but not from MyD88    mice (Figs. 1 and 4). Osteoclast
precursors from MyD88    mice and WT mice similarly dif-
ferentiated into osteoclasts in response to RANKL plus
M-CSF, but the extent of osteoclast formation induced by
1,25(OH)2D3 plus PGE2 in the MyD88    mice was always
significantly less than that in wild-type cocultures (Fig. 1). This
suggests that MyD88 is involved in osteoblast function includ-
ing the support of osteoclasts in response to 1,25(OH)2D3 plus
PGE2. LPS, diacyl lipopeptide, and IL-1  stimulated expres-
sion of RANKL mRNA in WT and TRIF    osteoblasts, but
not MyD88    osteoblasts (Figs. 2 and 4). These results sug-
gest that RANKL expression in osteoblasts through MyD88-
mediated signals is a key step in osteoclast formation induced
by LPS, diacyl lipopeptide, and IL-1 (Fig. 8).
Figure 7. Histomorphometric
analysis of vertebrae in WT and
MyD88    mice. (A) Seven male
MyD88    and WT (14-wk-old)
mice each were killed for bone
histomorphometric analysis. Ver-
tebrae  were removed from the
mice, fixed in 70% ethanol, and
embedded in glycol-methacrylate
without decalcification. Sections
were prepared and stained with
Villanueva Goldner to discrimi-
nate between mineralized and
unmineralized bone and to iden-
tify cellular components. Quan-
titative histomorphometric anal-
ysis was done in a double-blind
fashion. Values were expressed as
the mean   SD of seven mice.
Statistical analysis was performed
using Student’s t test. Significant
difference between WT and
MyD88    mice (*, P   0.005;
**, P   0.05; ***, P   0.01). (B)
Histological evaluation (double
staining of TRAP and meth-
ylgreen) of femoral trabecular
bones obtained from male
MyD88    and WT (12-wk-old)
mice. TRAP positive osteoclasts
appeared dark red. Arrowheads
indicate osteoblasts along the
bone surface. Bars, 500  m.
Figure 8. Roles of MyD88
and TRAM–TRIF signaling path-
ways in macrophages, osteoblasts,
and osteoclasts exposed to LPS,
IL-1, diacyl lipopeptide, and
RANKL. (A) Role of MyD88-
and TRAM–TRIF-mediated sig-
naling in IL-6 production in
macrophages. Macrophages ex-
press CD14 and TLR4. Both
MyD88-dependent and TRAM–
TRIF-dependent pathways medi-
ated by TLR4 were essential for
IL-6 production in macrophages.
(B) Roles of MyD88-mediated
signals in IL-6 production and
osteoclast formation in osteo-
blasts. Osteoblasts express CD14,
TLR2, TLR4, TLR6, and IL-1R. LPS stimulates IL-6 production through MyD88 signaling. LPS, IL-1, and diacyl lipopeptide stimulate RANKL ex-
pression in osteoblasts through the respective receptor systems. TLR- and IL-1R–induced RANKL mRNA expression in osteoblasts is mediated
through MyD88 signaling followed by PKC and MEK/ERK signaling. (C) Role of MyD88-mediated signals in osteoclast function. Mature osteoclasts
express CD14, TLR4, and IL-1R as well as RANK. LPS, IL-1, and RANKL stimulate the survival of osteoclasts through TLR4, IL-1R, and RANK,
respectively. MyD88 is involved in the survival of osteoclasts supported by LPS and IL-1, but not by RANKL.Sato et al. 609
LPS and IL-1  stimulated phosphorylation of ERK1/2
in WT osteoblasts, but not MyD88    osteoblasts (Fig. 3).
The elevated calcium concentration (5 mM) in the culture
medium stimulated both phosphorylation of ERK1/2 and
RANKL mRNA expression in WT and MyD88    osteo-
blasts. This calcium concentration did not appear to be
toxic to the cells. A serine threonine kinase, Cot, also
known as tumor progression locus 2 (Tpl2), has been
shown to be an essential kinase in LPS-induced TNF 
production in mouse macrophages (34, 35). Cot/Tpl2 acti-
vated ERK, but not JNK and p38 MAPK, in the LPS-
treated macrophages. It was reported that both RANKL
mRNA induction and ERK activation by LPS were mark-
edly reduced in osteoblasts prepared from Cot/Tpl2-defi-
cient mice (36). These results suggest that LPS-induced
RANKL mRNA expression is mediated through MyD88
followed by PKC and MEK/ERK signals rather than JNK
and p38 MAPK signals (Fig. 8).
We reported previously that osteoclasts formed in vitro
expressed TLR4 and CD14, and LPS directly supported
the survival and stimulated the dentine-resorbing activity of
osteoclasts (32). Takami et al. (33) showed that mouse bone
marrow macrophages expressed all known TLRs (TLR1–
TLR9), but mouse osteoclasts expressed only TLR2 and
TLR4. Consistent with these findings, LPS and IL-1  but
not diacyl lipopeptide (a ligand for the TLR2 plus TLR6
complex) stimulated the survival of osteoclasts derived from
WT and TRIF    mice (Fig. 5). The survival of osteoclasts
from MyD88    mice was supported by RANKL, but not
by LPS and IL-1 . These results suggest that MyD88 but
not TRIF is involved in IL-1R– and TLR4-mediated sig-
naling in the survival of osteoclasts. MyD88 and RANK
are shown to associate with TNF receptor-associated factor
6 to induce their signals in target cells. TNF receptor-asso-
ciated factor 6 appears to be a common signaling molecule
downstream of MyD88 and RANK in osteoclasts.
Recent studies using TRIF    mice showed the essential
role of TRIF in the MyD88-independent pathways of
TLR3 and TLR4 signaling (17, 18). TRAM was shown to
be involved in the TLR4-mediated TRIF-signaling path-
way in the innate immune response to LPS (19, 20). Con-
sistent with previous findings, TRIF    macrophages abol-
ished the response to LPS in IL-6 production (Fig. 4).
However, surprisingly, TRIF    osteoblasts and TRIF   
osteoclasts responded to LPS as those from WT mice did.
Osteoblasts and osteoclasts expressed TRIF but not
TRAM, suggesting that TRAM expression is required for
TRIF-mediated action in osteoblasts and osteoclasts (Fig.
8). Our results also suggest that TRAM may be an impor-
tant key adaptor in the TLR4-mediated pathway of cell-
specific functions.
At present, it is unknown why immune cells such as
macrophages and B cells required both MyD88 and TRIF
signaling in response to LPS. We reported previously that
LPS stimulated the production of proinflammatory cyto-
kines such as IL-1 , TNF- , and IL-6 in bone marrow
macrophages but not in osteoclasts (32). Thus, osteoclasts
respond to LPS through TLR4, but the characteristics of
osteoclasts are quite different from those of their precursors,
bone marrow macrophages. These results suggest that
TRIF is important for the function of immune cells, but
not that of nonimmune cells such as osteoblasts and osteo-
clasts. Loss of immune responsiveness to LPS in osteoclasts
must be a requirement for performing essential roles in
physiological bone turnover. Further studies will elucidate
the significance of the requirement of TRAM–TRIF sig-
nals in immune cells.
MyD88    mice exhibited a significant decrease in tra-
becular bone volume and trabecular number in vertebrae,
although no significant differences in body size and shape
were observed between MyD88    and WT mice. Not
only bone resorption–related parameters but also bone for-
mation–related parameters were significantly decreased in
MyD88    mice in comparison with WT mice (Fig. 7).
Mice deficient in bone matrix proteins such as osteonectin
and biglycan similarly developed profound osteopenia with
a decrease of bone formation and resorption (37–39). Defi-
ciency of OPG in mice induced severe osteoporosis caused
by enhanced bone resorption, but accelerated bone forma-
tion was also observed in these mice (27, 40). These find-
ings suggest that bone formation is tightly coupled with
bone resorption.
In conclusion, MyD88 but not TRIF plays essential roles
in RANKL expression in osteoblasts in response to IL-1
and TLR ligands. MyD88 is also a key molecule for osteo-
clast function induced by IL-1 and LPS. MyD88    mice
exhibit osteopenia with reduced bone resorption and bone
formation. Thus, MyD88-mediated signaling plays impor-
tant roles not only in bone resorption induced by inflam-
matory diseases but also in ordinary bone metabolism. Fur-
ther studies are necessary to clarify the physiological and
pathological significance of MyD88 signals in bone resorp-
tion and bone formation.
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